GILD: Diversified pipeline advances in HIV, oncology, and inflammation set up multiple launches and key data
The company is advancing a diversified pipeline across virology, oncology, and inflammation, with multiple new launches and promising clinical data expected in the next year. Key assets include long-acting HIV regimens, novel cell therapies, ADCs, and innovative inflammation treatments.Based on Gil…